October 4, 2012
FDG-PET's ability to assess metabolic tumors appears to be a valuable asset in determining the biology of colorectal liver metastases (CRLM) before surgical resection and may better evaluate patient prognosis, according to a study in the September issue of the Journal of Nuclear Medicine.